Financial analyst and former drug company executive Richard Evans said the administration plan would help bring down costs, but not to the same degree as giving Medicare a direct role in setting prices.
Trump's big promises on drug costs followed by modest steps →
"I don't see Prop. 61 as being a constructive answer to drug pricing issues," said Richard Evans, a health care analyst for SSR, an investment research firm.
Big pharma spending big dollars to defeat California measure →
